Evidence map›Paper›PMID 10984531›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.

Z Shriver, R Raman, G Venkataraman, K Drummond, J Turnbull, T Toida, R Linhardt, K Biemann, R Sasisekharan

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 81 citations in OpenAlex.

  1. Informatics Ecosystems to Advance the Biology of Glycans.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Therapeutically targeting protein-glycan interactions.British journal of pharmacology · 2009
    Review
  16. Article
  17. Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  18. Article
  19. Article
  20. Rational design of low-molecular weight heparins with improved in vivo activity.Proceedings of the National Academy of Sciences of the United States of America · 2003
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Z ShriverDivision of Bioengineering and Environmental Health, Harvard-Massachusetts Institute of Technology, Biomedical Engineering, Cambridge, MA 02139, USA.
R Raman
G Venkataraman
K Drummond
J Turnbull
T Toida
R Linhardt
K Biemann
R Sasisekharan
Bioengineering Center · RU

Funding

Structure-Function Relationship of GlycosaminoglycansR37GM057073 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SASISEKHARAN, RAM · 2010 to 2019
$3.9M
Sequence Analysis of GlycosaminoglycansR01GM057073 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SASISEKHARAN, RAM · 1998 to 2010
$3.1M
NIGMS NIH HHS GM 57073NIGMS NIH HHS R01 GM057073NIGMS NIH HHS R37 GM057073
6 · The paper itself

Abstract

Heparin- and heparan sulfate-like glycosaminoglycans (HLGAGs) represent an important class of molecules that interact with and modulate the activity of growth factors, enzymes, and morphogens. Of the many biological functions for this class of molecules, one of its most important functions is its interaction with antithrombin III (AT-III). AT-III binding to a specific heparin pentasaccharide sequence, containing an unusual 3-O sulfate on a N-sulfated, 6-O sulfated glucosamine, increases 1,000-fold AT-III's ability to inhibit specific proteases in the coagulation cascade. In this manner, HLGAGs play an important biological and pharmacological role in the modulation of blood clotting. Recently, a sequencing methodology was developed to further structure-function relationships of this important class of molecules. This methodology combines a property-encoded nomenclature scheme to handle the large information content (properties) of HLGAGs, with matrix-assisted laser desorption ionization MS and enzymatic and chemical degradation as experimental constraints to rapidly sequence picomole quantities of HLGAG oligosaccharides. Using the above property-encoded nomenclature-matrix-assisted laser desorption ionization approach, we found that the sequence of the decasaccharide used in this study is DeltaU(2S)H(NS,6S)I(2S)H(NS, 6S)I(2S)H(NS,6S)IH(NAc,6S)GH(NS,3S,6S) (+/-DDD4-7). We confirmed our results by using integral glycan sequencing and one-dimensional proton NMR. Furthermore, we show that this approach is flexible and is able to derive sequence information on an oligosaccharide mixture. Thus, this methodology will make possible both the analysis of other unusual sequences in HLGAGs with important biological activity as well as provide the basis for the structural analysis of these pharamacologically important group of heparin/heparan sulfates.

Indexed as

Antithrombin IIIBinding SitesCarbohydrate SequenceHeparinMagnetic Resonance SpectroscopyMolecular Sequence DataOligosaccharidesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntithrombin IIIHeparinOligosaccharides

Identifiers

PMID10984531
PMCPMC27029
OpenAlexW1990288607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.